Chronic Inflammatory Demyelinating PolyneuropathySymptoms, Doctors, Treatments, Advances & More
Chronic Inflammatory Demyelinating Polyneuropathy Overview
Learn About Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a disorder that involves nerve swelling and irritation (inflammation) that leads to a loss of strength or sensation.
Chronic inflammatory demyelinating polyradiculoneuropathy; Polyneuropathy - chronic inflammatory; CIDP; Chronic inflammatory polyneuropathy; Guillain-Barré - CIDP
CIDP is one cause of damage to nerves outside the brain or spinal cord (peripheral neuropathy). Polyneuropathy means several nerves are involved. CIDP often affects both sides of the body.
CIDP is caused by an abnormal immune response. CIDP occurs when the immune system attacks the myelin cover of the nerves. For this reason, CIDP is thought to be an autoimmune disease.
Health care providers also consider CIDP as the chronic form of Guillain-Barré syndrome.
The specific triggers of CIDP vary. In many cases, the cause cannot be identified.
CIDP may occur with other conditions, such as:
- Chronic hepatitis
- Diabetes
- Infection with the bacterium Campylobacter jejuni
- HIV/AIDS
- Immune system disorders due to cancer
- Inflammatory bowel disease
- Systemic lupus erythematosus
- Cancer of the lymph system
- Overactive thyroid
- Side effects of medicines to treat cancer or HIV
Symptoms include any of the following:
- Problems walking due to weakness or lack of feeling in the feet
- Trouble using the arms and hands or legs and feet due to weakness
- Sensation changes, such as numbness or decreased sensation, pain, burning, tingling, or other abnormal sensations (usually affects the feet first, then the arms and hands)
Other symptoms that can occur with CIDP include:
- Abnormal or uncoordinated movement
- Problems breathing
- Fatigue
- Hoarseness or changing voice or slurred speech
The goal of treatment is to reverse the attack on the nerves. In some cases, nerves can heal and their function can be restored. In other cases, nerves are badly damaged and cannot heal, so treatment is aimed at preventing the disease from getting worse.
Which treatment is given depends on how severe the symptoms are, among other things. The most aggressive treatment is only given if you have difficulty walking, breathing, or if symptoms don't allow you to care for yourself or work.
Treatments may include:
- Corticosteroids to help reduce inflammation and relieve symptoms
- Other medicines that suppress the immune system (for some severe cases)
- Plasmapheresis or plasma exchange to remove antibodies from the blood
- Intravenous immune globulin (IVIg), which involves injecting antibodies into the bloodstream to reduce the effect of the antibodies that are causing the problem
Vickie & Jack Farber Institute For Neuroscience - Honickman Center
Marinos Dalakas is a Neurologist and a Neuromusculoskeletal Medicine provider practicing medicine in Philadelphia, Pennsylvania. Dr. Dalakas is rated as an Elite provider by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Stiff Person Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, Hereditary Hyperekplexia, Chronic Polyradiculoneuritis, and Laminectomy. Dr. Dalakas is board certified in Neurology. Dr. Dalakas is currently accepting new patients.
Clinical Research Center
Mazen Dimachkie is a Neurologist practicing medicine in Fairway, Kansas. He has been practicing medicine for over 38 years. Dr. Dimachkie is rated as an Elite provider by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Myositis, Inclusion Body Myositis, Myasthenia Gravis, Thymectomy, and Tissue Biopsy. Dr. Dimachkie is board certified in United Council For Neurologic Subspecialties, Clinical Neuromuscular Pathology - 2015 , American Board Of Psychiatry And Neurology, Neuromuscular Medicine - 2008 , American Board Of Psychiatry And Neurology, Clinical Neurophysiology - 1996 , and American Board Of Psychiatry And Neurology, Neurology - 1995. Dr. Dimachkie is currently accepting new patients.
Clinical Research Center
Mamatha Pasnoor is a Neurologist practicing medicine in Fairway, Kansas. She has been practicing medicine for over 30 years. Dr. Pasnoor is rated as an Elite provider by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Thymectomy, and Tissue Biopsy. Dr. Pasnoor is board certified in American Board Of Psychiatry And Neurology, Clinical Neurophysiology - 2009 , American Board Of Psychiatry And Neurology, Neuromuscular Medicine - 2008 , and American Board Of Psychiatry And Neurology, Neurology - 2006. Dr. Pasnoor is currently accepting new patients.
The outcome varies. The disorder may continue long term, or you may have repeated episodes of symptoms. Complete recovery is possible, but permanent loss of nerve function is not uncommon.
Complications of CIDP include:
- Pain
- Permanent decrease or loss of sensation in areas of the body
- Permanent weakness or paralysis in areas of the body
- Repeated or unnoticed injury to an area of the body
- Side effects of medicines used to treat the disorder
Contact your provider if you have a loss of movement or sensation in any area of the body, especially if your symptoms get worse.
Summary: The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Summary: The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
Published Date: June 13, 2024
Published By: Joseph V. Campellone, MD, Department of Neurology, Cooper Medical School at Rowan University, Camden, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Katirji B. Disorders of peripheral nerves. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 106.
Smith AG, Shy ME. Peripheral neuropathies. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 388.


